Position in REGN
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,362,434
-$322,693 QoQ
Shares Held
2,185
+0.2% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#592
of 1,329 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Savvy Advisors, Inc. holds $15,531,812 across 11 Biotechnology names. REGN ranks #2 (8.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VIR |
Vir Biotechnology, Inc.
|
1,040,665 | $10,604,376 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
This page
|
2,185 | $1,362,434 | |
| 3 | DNLI |
Denali Therapeutics Inc.
|
45,194 | $1,162,389 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,881 | $934,349 | |
| 5 | INCY |
Incyte Corp
|
5,248 | $594,913 | |
| 6 | TWST |
Twist Bioscience Corp
|
2,511 | $258,331 | |
| 7 | AGIO |
Agios Pharmaceuticals, Inc.
|
6,794 | $252,125 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
5,290 | $206,362 |
All Filings in REGN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,362,434 | 2,185 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $1,685,127 | 2,181 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,699,657 | 2,202 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $1,091,928 | 1,942 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $832,125 | 1,585 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $764,881 | 1,206 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $886,850 | 1,245 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||